Samuel Blackman compensation by year
Day One Biopharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $470,000 | $500,000 | $527,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $270,940 | $538,430 | $1,400,680 |
| Option awards | $1,143,057 | $1,206,462 | $1,381,724 |
| Non-equity incentive | $181,000 | $227,300 | $291,700 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $12,200 | $13,200 | $13,800 |
| Total | $2,077,197 | $2,485,392 | $3,614,904 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Day One Biopharmaceuticals, Inc. DEF 14A filed April 11, 2025, accession 0001140361-25-013462, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 72,752 | $921,768 | — |
| RSU | 11,504 | $145,756 | — |
| RSU | 5,144 | $65,174 | — |
| RSU | 4,756 | $60,259 | — |
| Option | 37,500 | — | $23.41 |
| Option | 36,569 | — | $14.26 |
| Option | 18,907 | — | $16.00 |
| Option | 114,087 | — | $14.44 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Day One Biopharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Day One Biopharmaceuticals discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $0 | $0 | $0 | $0 |
| Change in control and involuntary termination | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in Day One Biopharmaceuticals, Inc.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
Day One Biopharmaceuticals’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Jeremy Bender | Chief Executive Officer and President | $6,560,577 |
| Charles York | Chief Operating Officer and Chief Financial Officer | $3,896,080 |
| Samuel Blackman · this page | Co-Founder and Head of Research and Development | $3,614,904 |
| Adam Dubow | General Counsel, Chief Compliance Officer and Secretary | $2,385,614 |
The full Day One Biopharmaceuticals compensation record
free company briefThis page is one person within Day One Biopharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Day One Biopharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Day One Biopharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat